UNIVERSITY OF CRETE

A European epilepsy drug, sulthiame, shows potential as a treatment for sleep apnea, reducing breathing pauses and increasing blood oxygen levels in a clinical trial. Sulthiame, not approved in the U.S., targets the respiratory system by inhibiting carbonic anhydrase, stimulating upper airway muscles. Further trials are needed to confirm its benefits and long-term effects.

Sulthiame, an epilepsy drug used in Europe, showed potential in treating sleep apnea, reducing breathing pauses and increasing blood oxygen levels in a clinical trial. However, further trials are needed to confirm its efficacy and safety.